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Abstract
Background: Diabetes Mellitus (DM) is a major cause of morbidity and mortality affecting millions
of people worldwide, while placing a noteworthy strain on public health funding. The aim of this
study was to assess health-related quality of life (HRQOL) of Greek Type II DM patients and to
identify significant predictors of the disease in this patient population.
Methods: The sample (N = 229, 52.8% female, 70.0 years mean age) lived in a rural community of
Lesvos, an island in the northeast of the Aegean Archipelagos. The generic SF-36 instrument,
administered by trainee physicians, was used to measure HRQOL. Scale scores were compared
with non-parametric Mann-Whitney and Kruskal-Wallis tests and multivariate stepwise linear
regression analyses were used to investigate the effect of sociodemographic and diabetes-related
variables on HRQOL.
Results:  The most important predictors of impaired HRQOL were female gender, diabetic
complications, non-diabetic comorbidity and years with diabetes. Older age, lower education, being
unmarried, obesity, hypertension and hyperlipidaemia were also associated with impaired HRQOL
in at least one SF-36 subscale. Multivariate regression analyses produced models explaining
significant portions of the variance in SF-36 subscales, especially physical functioning (R2 = 42%), and
also showed that diabetes-related indicators were more important disease predictors, compared
to sociodemographic variables.
Conclusion: The findings could have implications for health promotion in rural medical practice
in Greece. In order to preserve a good HRQOL, it is obviously important to prevent diabetes
complications and properly manage concomitant chronic diseases. Furthermore, the gender
difference is interesting and requires further elucidation. Modifying screening methods and medical
interventions or formulating educational programs for the local population appear to be steps in
the correct direction.
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Background
Diabetes Mellitus (DM) is a major cause of morbidity and
mortality and places a huge strain on public health fund-
ing [1]. At present, the disease has reached epidemic pro-
portions, affecting more than 170 million people
worldwide, with an estimated increase of at least 50% by
2010, especially in developing countries, and expected to
double to about 300 million by the year 2025. Globally,
this represents a 42% increase in the number of people
with diabetes, producing an approximate overall 27%
increase in the prevalence of the disease [2]. Diabetes
complications have important effects on patients' quality
of life as well as socio-economic implications [3].
Measuring health-related quality of life (HRQOL) in Type
II DM is important for several reasons such as dietary
restrictions, medication and the actual symptoms of this
disease as well as concomitant diseases, all of which may
lead to deteriorations in HRQOL. Moreover, the guide-
lines for treatment of Type II DM emphasize that one of
the primary objectives is to improve HRQOL [4]. This
implies that HRQOL is increasingly used as an outcome
measure to monitor the burden of DM on the population
and the results of previous studies show that HRQOL is
associated with duration of diabetes [5], age [6], female
gender [7,8], diabetic complications [9,10], concomitant
diseases [11,12] and disease severity [13].
Many studies of HRQOL in diabetic patients have been
performed and comprehensive reviews are available in the
literature [14,15]. Various domains of functioning and
well-being contribute uniquely to overall HRQOL, imply-
ing that a multidimensional measurement approach is
required [16]. In light of this, the majority of quality of life
studies involving diabetics have been performed using
multidimensional assessment including physical, psycho-
logical, and social functioning and well-being. The two
major approaches to measuring HRQOL are generic and
disease-specific instruments, and the two have been com-
pared [17,18] in diabetes patients and shown to demon-
strate complementarity and provide different kinds of
information, with the generic ones perhaps providing
more information than their disease-specific counterparts
[19].
The prevalence of diabetes is highest in older adults whose
quality of life is of great concern, and many studies have
examined the relationship between diabetes and HRQOL
among this population [20-22]. Furthermore, the increas-
ing prevalence of diabetes, both in urban [23,24] and
rural [25,26] areas in Greece, has been shown. However,
there is only a small amount of information on the asso-
ciation of sociodemographic and disease-specific factors
with the HRQOL of Greek Type II DM patients. Therefore,
the aim of this study was to use a generic multidimen-
sional instrument (SF-36) to identify significant disease-
specific and sociodemographic predictors of diabetes in
this rural patient population.
Methods
Sample and data collection
The subjects in this study were Type II DM patients living
in the area served by the Health Center of Plomari, located
on the island of Lesvos in the northeastern part of the
Aegean Archipelagos. Patients were recruited from the
health center's database of 5.986 adults residing within in
its service area, and of whom 469 (7.8%) have been iden-
tified as diabetics. Trainee physicians met with patients
consecutively during their routine visits to the health
center or to one of its affiliated rural posts and collected
information via interview, clinical observation and by
reviewing the patients' medical records, as it has been sug-
gested that these data sources supplement each other in
providing reliable clinical data [27]. The study was con-
ducted in the second half of 2005 and 229 patients, out of
254 visiting the health center during the study period,
agreed to participate (90.2% response rate). The survey
included the SF-36 quality of life instrument, socio-demo-
graphic and diabetes-specific questions. The heath
center's administration, in cooperation with the review
board of the supervising general hospital of Mytilini,
granted ethical approval for this study and all subjects
provided informed consent.
Measurement of HRQOL
The SF-36 health survey contains 36 questions covering
functional health status and general health, currently and
over the previous 4 weeks [28], and has been validated in
a Greek general population [29]. The questions are sum-
marized into eight scales measuring physical functioning
(PF), role physical (RP), bodily pain (BP), general health
perception (GH), vitality (VT), social functioning (SF),
role emotional (RE), and mental health (MH), with
higher scores (0–100 range) reflecting better-perceived
health. Previous studies have shown that the instrument
discriminates well between perceptions of people with or
without one or more chronic diseases [30-32], and
between people with and without diabetes [33-35].
Statistical Analyses
The SF-36 subscales were scored according to documented
procedures [36]. Internal consistency reliability of each
scale was calculated using Cronbach's alpha and the 0.70
standard for group-level comparisons was adopted [37].
Normality was tested with the Kolmogorov-Smirnov  test.
Subscale scores were compared within groups, using
Mann-Whitney and Kruskal-Wallis nonparametric tests, for
each sociodemographic and diabetes-related independent
variable. Multivariate stepwise linear regression analyses
(with the eight SF-36 subscales as the dependent varia-BMC Public Health 2007, 7:186 http://www.biomedcentral.com/1471-2458/7/186
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bles) were performed to investigate the relationships
between HRQOL scores, sociodemographic variables and
data concerning the disease and its therapy. Specifically,
independent variables included in the analyses were gen-
der, age, marital status, education, employment, BMI,
micro- and macrovascular complications, hypertension,
hyperlipidaemia, years with diabetes and concomitant
chronic diseases. Relationships were considered statisti-
cally significant when p-values ≤ 0.05 were reached. All
analyses were performed with SPSS version 13.0 (SPSS
Inc. Chicago, IL, USA).
Results
Socio-demographic and diabetes-related data are pre-
sented in Table 1. Most respondents are female (52.8%)
and the mean age, for the entire sample, is 70.0 years. The
majority is of low educational status, having completed
only primary school (82.1%). Most patients are married
(74.0%) and retired (42.7%). Regarding diabetes, the
average duration is approximately 10 years. The majority
of patients (95.2%) reported suffering from at least one
other chronic (non-diabetic) medical condition such as
hypertension (76.9%) and/or hyperlipidaemia (42.5%).
Diabetic complications are prevalent in this sample. Spe-
cifically, 23.6% suffer from microvascular diseases -
mostly angiopathy and retinopathy- and 31.4% from
macrovascular complications, mostly cardiovascular dis-
ease. Finally, most patients control their diabetes via diet
(74.9%) and antidiabetic medication (70.9%) and 87.3%
regularly take medication (mostly antihypertensive and
antilipidaemic) for other health problems.
Central tendency, variability and reliability of the SF-36
scales are presented in Table 2. The percentage of valid
responses was high in all scales as a result of interviewing
the patients. Two scales, RP and RE, suffer floor effects
because the relevant questions are dichotomous (the only
ones in the instrument) and generate fewer possible
response levels. Concerning reliability, all scales meet the
recommended >0.70 internal consistency criterion. The
eight subscale scores range from 48.9 for GH to 74.8 for
SF. Scores were computed and compared according to
sociodemographic characteristics of the sample, and the
results are shown in Table 3.
Kolmogorov-Smirnov normality tests showed non-nor-
mal distributions for PF, RP, BP, SF and RE (P < 0.001),
MH (P < 0.01) and VT (P < 0.05), therefore non-paramet-
ric Mann-Whitney and Kruskal-Wallis tests were used for
comparisons. Females reported statistically significantly
lower quality of life in all domains, specifically PF, BP, VT,
and SF (P < 0.001), GH, RE and MH (P < 0.01) and RP (P
< 0.05). Regarding age, only PF scores deteriorate signifi-
cantly in older age-groups (P < 0.001), however the scores
for the other subscales are in the expected directions as
well. This particular sample is comprised mostly of elderly
patients, implying that age is not expected to discriminate
well between quality of life levels. The same holds for two
other social variables, i.e. marital status and education. As
75% of the sample is married and over 80% are of the
same (low) educational status, these variables will also be
poor discriminators. In any case, married patients
reported better health in all scales and the differences were
significant for BP, VT and MH (P < 0.05). Similarly educa-
tion is a significant discriminating variable for PF (P <
0.001), BP (P < 0.01), RP, VT, SF and MH (P < 0.05).
Similar analyses were performed using diabetes-related
data as discriminators of HRQOL (Table 4). Duration of
the disease appears to be the most influential factor as it
Table 1: Characteristics of the sample (N = 229) of diabetic patients in a Greek rural society
Demographics N (% valid) Diabetes-related data N (% valid)
Gender (female) 121 (52.8) Body mass index (Kg/m2) (mean ± SD) 30.4 ± 5.2
Age (mean ± SD) 70.0 ± 9.9 Prevalence of diabetic complications
Education (years) Microvascular 54 (23.6)
≤ 6 183 (82.1) Angiopathy 35 (15.8)
7–12 31 (13.9) Retinopathy 25 (11.1)
> 12 9 (4.0) Neuropathy 19 (8.5)
Family status Nephropathy 7 (3.1)
Single 9 (4.0) Macrovascular 72 (31.4)
Married 165 (74.0) Comorbidity* 218 (95.2)
Divorced/Separated 1 (0.4) Hypertension 176 (76.9)
Widowed 48 (21.6) Hyperlipidemia 93 (42.5)
Occupational status Years with diabetes (mean ± SD) 10.0 ± 8.3
Retired 93 (42.7) Smoking 21 (9.6)
Farming 46 (21.1) Diabetes control method
Other 22 (10.1) Diet 146 (74.9)
Keeping house 57 (26.1) Medication 161 (70.9)
Insulin 27 (11.9)
Other medication 200 (87.3)
* One or more chronic medical conditionsBMC Public Health 2007, 7:186 http://www.biomedcentral.com/1471-2458/7/186
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Table 3: SF-36 subscale scores according to demographic characteristics of the sample (N = 229)
PF RP BP GH VT SF RE MH
Sex
Male 74.6 69.2 81.7 53.3 63.3 85.0 72.6 65.7
Female 55.4 55.4 65.3 45.0 50.6 65.8 55.7 55.1
P (sig.) 0.000*** 0.016* 0.000*** 0.007** 0.000*** 0.000*** 0.007** 0.003**
Age
≤ 65 74.7 66.7 72.4 51.2 62.4 76.7 65.7 61.4
66–75 62.4 63.8 72.5 47.4 54.4 74.3 64.8 59.3
> 75 56.5 54.5 74.2 48.4 53.3 73.5 59.7 59.8
P (sig.) 0.000*** 0.380 0.925 0.578 0.084 0.812 0.659 0.799
Marital Status
Married 66.3 64.9 76.2 49.7 59.3 76.4 66.5 62.1
Single/Widowed 59.6 53.5 65.5 46.1 48.4 71.5 55.2 53.6
P (sig.) 0.078 0.078 0.021* 0.304 0.011* 0.321 0.080 0.031*
Education
≤ 6 years 60.5 57.3 69.4 46.8 54.0 72.0 60.3 57.8
7–12 years 81.6 81.5 85.6 54.6 65.3 85.9 71.0 65.1
> 12 years 81.7 72.2 91.1 58.9 63.8 80.6 81.5 76.4
P (sig.) 0.000*** 0.014* 0.002** 0.107 0.049* 0.022* 0.267 0.032*
Work Status
Retired 62.0 68.3 78.5 49.9 57.0 79.1 69.9 62.2
Employed/Farming 72.4 57.4 77.7 50.7 60.0 78.2 59.8 61.8
Keeping House 58.6 56.3 61.9 47.3 52.4 64.5 58.5 54.8
P (sig.) 0.013* 0.159 0.004** 0.788 0.375 0.031* 0.180 0.226
*** P <0.001, ** P <0.01, * P <0.05 according to Mann-Whitney or Kruskal-Wallis test.
Abbreviations: PF = Physical Functioning, RP = Role Physical, BP = Bodily Pain, GH = General Health, VT = Vitality, SF = Social Functioning, RE = 
Role Emotional, MH = Mental Health
Table 2: Central tendency, variability and reliability of the SF-36 subscales
No. of Items % N Valid Mean (SD) 95% CI Median Floor (%) Ceiling (%) Reliability1
Scales
Physical functioning 10 99.6 64.5 (29.5) 60.7–68.4 75.0 0.4 9.2 0.94
Role physical 4 99.6 62.0 (45.8) 56.0–67.9 100.0 30.7 55.7 0.96
Bodily pain 2 99.6 73.0 (30.5) 69.0–76.9 84.0 2.6 46.1 0.92
General health 5 99.1 48.9 (23.0) 45.9–51.9 47.0 1.8 0.4 0.76
Vitality 4 99.6 56.9 (27.4) 53.0–60.2 60.0 2.6 4.4 0.88
Social functioning 2 98.7 74.8 (29.7) 70.9–78.7 87.5 2.2 44.2 0.84
Role emotional 3 99.6 63.6 (45.0) 57.7–69.5 100.0 29.8 56.6 0.93
Mental health 5 98.7 60.1 (26.3) 56.7–63.5 64.0 0.9 1.3 0.85
1Measured with Cronbach's alpha coefficientBMC Public Health 2007, 7:186 http://www.biomedcentral.com/1471-2458/7/186
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negatively and statistically significantly affects all SF-36
subscales, especially in the case of the ">10 years" group.
Micro- and macrovascular complications also demon-
strate a negative influence on six and five quality of life
subscales respectively. As expected, the absence of diabe-
tes complications results in improved HRQOL, however
statistical insignificance is observed for RP and BP, and for
RE in the case of macro-complications. The coexistence of
non-diabetic comorbidity generally results in lower scale
scores, and the differences are significant for PF (P < 0.01),
BP, GH and SF (P < 0.05). Hypertension and hyperlipi-
daemia also affect HRQOL in a negative manner, with the
most significant differences appearing in the GH and MH
subscale scores respectively (P < 0.001). Concerning body
mass index, patients in the "normal" range (<25 Kg/m2)
report higher scores than those in the "overweight" and
"obese" ranges, however the differences are statistically
significant only for PF (P < 0.05).
Multivariate analyses for the SF-36 (Table 5) showed that
sex (female) had the most pronounced negative influence
on HRQOL. Other sociodemographic factors were signifi-
cant predictors for certain SF-36 subscale scores, e.g. older
age is associated with lower PF and RE scores (P < 0.01),
being married with higher VT (P < 0.05), higher education
with less BP (P < 0.05) and being employed with worse
GH (P < 0.05) and more emotional role limitations (P <
0.01). As for the diabetes-specific factors, microvascular
Table 4: SF-36 subscale scores according to health-related characteristicsof the sample (N = 229)
PF RP BP GH VT SF RE MH
Body mass index
< 25 Kg/m2 74.7 74.2 82.7 54.9 66.3 81.5 71.3 69.5
25–30 Kg/m2 67.0 58.6 72.8 48.4 54.4 73.6 59.3 58.2
> 30 Kg/m2 60.5 62.6 71.7 49.0 56.5 74.7 66.4 59.6
P (sig.) 0.038* 0.250 0.217 0.425 0.123 0.450 0.312 0.103
Microvascular Complications
Yes 49.0 50.5 66.6 39.2 46.5 64.2 48.2 51.8
No 69.2 65.4 74.9 51.9 59.7 78.1 68.4 62.7
P (sig.) 0.000*** 0.059 0.072 0.000*** 0.000*** 0.002** 0.009** 0.009**
Macrovascular Complications
Yes 50.4 52.5 72.1 41.4 46.8 68.8 56.9 54.5
No 70.9 66.2 73.4 52.4 61.1 77.7 66.7 62.7
P (sig.) 0.000*** 0.059 0.995 0.000*** 0.000*** 0.021* 0.092 0.031*
Hypertension
Yes 62.7 60.6 71.8 46.1 54.4 73.1 62.7 58.6
No 70.5 66.5 76.9 58.0 63.8 80.5 66.7 64.8
P (sig.) 0.047* 0.446 0.224 0.000*** 0.027* 0.118 0.527 0.126
Hyperlipidaemia
Yes 58.8 57.9 66.7 45.4 50.4 70.4 58.1 52.7
No 67.1 62.0 76.5 51.0 59.7 77.4 66.4 64.4
P (sig.) 0.049* 0.287 0.022* 0.037* 0.016* 0.079 0.176 0.000***
Years with diabetes
< 5 67.6 59.8 75.7 54.3 61.0 78.9 69.8 65.9
5–10 69.7 74.0 78.7 51.6 61.6 81.1 68.8 61.7
> 10 56.4 52.0 64.6 41.3 47.4 64.8 52.4 53.1
P (sig.) 0.016* 0.017* 0.011* 0.000*** 0.002** 0.000*** 0.038** 0.008**
≥ 1 other diseases
Yes 61.6 61.6 70.4 46.6 54.5 71.9 62.0 58.8
No 73.8 66.0 79.4 55.4 62.5 83.3 70.4 63.9
P (sig.) 0.004** 0.595 0.027* 0.012* 0.060 0.022* 0.208 0.188
*** P <0.001, ** P <0.01, *P <0.05 according to Mann-Whitney or Kruskal-Wallis test.
Abbreviations: PF = Physical Functioning, RP = Role Physical, BP = Bodily Pain, GH = General Health, VT = Vitality, SF = Social Functioning, RE = 
Role Emotional, MH = Mental HealthBMC Public Health 2007, 7:186 http://www.biomedcentral.com/1471-2458/7/186
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complications and disease duration were the most signif-
icant predictors of HRQOL, each affecting negatively and
significantly five SF-36 subscales. The presence of other
chronic diseases is also a significant predicting factor for
four subscales. It appears that PF is the HRQOL dimen-
sion most significantly influenced by sociodemographic
and disease-related factors, and this is reflected by the
high portion of variance explained by the linear regression
model (42%). For the other subscales, the models
explained portions of variance ranging between 15–26%,
except for the RE subscale which appears to be unaffected
(R2 = 0.043).
Discussion
We investigated the association of demographic, social
and diabetes-specific variables on the HRQOL of a sample
of elderly Greek Type II DM patients living on a remote
located island in the Aegean archipelagos. Evidence was
provided to support assertions made in previous studies,
that impaired HRQOL is associated with obesity [38],
micro- and macrovascular complications [39], hyperten-
sion [40], hyperlipidaemia [41] and non-diabetic comor-
bidity [42]. Furthermore, age, gender, marital status and
education were also confirmed as important discrimina-
tors of HRQOL in type II diabetics. All comparisons
showed differences in the expected directions and mostly
statistically significant. The most influenced SF-36 sub-
scale was PF since the differences, for all the variables
studied, were statistically significant except for marital sta-
tus, which was marginally insignificant (P = 0.078). Con-
trarily, the role limitations scales (RP and RE) were the
least affected, most likely due to their poor discriminating
ability mentioned previously.
The multivariate regression analyses (Table 5) indicate
that diabetes-related variables are more important predic-
tors of HRQOL, compared to demographic and social
characteristics of the sample. An obvious exception is gen-
der (female), which appears to be significant overall. Spe-
cifically, microvascular complications (mostly angiopathy
and retinopathy), disease duration and non-diabetic
comorbidity were the most profound predictors of a neg-
ative HRQOL, and when combined seemed to affect all
SF-36 subscales except for RP, which remained unaffected
with only 4.3% of its total variance explained in this
study. On the other hand PF, as expected according to the
Table 5: Multivariate analyses for SF-36 subscales
B Coefficient (p-value)
PF RP BP GH VT SF RE MH
Constant 147.4
(P <0.001)
90.0
(P <0.001)
93.4
(P <0.001)
26.0
(P = 0.045)
60.2
(P <0.001)
79.0
(P <0.001)
164.8
(P <0.001)
39.5
(P = 0.001)
Female -18.4
(P <0.001)
-19.0
(P = 0.006)
-15.0
(P = 0.001)
-8.3
(P =  0.012)
-12.8
(P = 0.001)
-21.2
(P <0.001)
-26.2
(P <0.001)
-11.9
(P = 0.002)
Age (per year) -1.0
(P <0.001)
-0.9
(P = 0.016)
Married 10.0
(P = 0.028)
Higher education 8.7
(P = 0.043)
Employed -8.1
(P = 0.029)
-22.1
(P = 0.004)
Body mass index (Kgr/m2)- 1 . 5
(P <0.001)
Microvascular complications -14.6
(P = 0.001)
-14.2
(P <0.001)
-11.7
(P = 0.016)
-19.2
(P = 0.015)
-12.9
(P = 0.006))
Macrovascular complications -13.3
(P <0.001)
-12.1
(P = 0.004))
Hypertension -9.5
(P = 0.010)
Hyperlipidemia -9.0
(P = 0.021)
Years with diabetes (per year) -0.7
(P = 0.007)
-0.5
(P = 0.025)
-0.6
(P = 0.014)
-0.7
(P = 0.006)
≥ 1 other diseases -10.3
(P = 0.013)
-10.3
(P = 0.005)
-10.2
(P = 0.022)
-11.0
(P = 0.015)
R2 = 0.42 0.04 0.15 0.22 0.20 0.26 0.18 0.13
Abbreviations: PF = Physical Functioning, RP = Role Physical, BP = Bodily Pain, GH = General Health, VT = Vitality, SF = Social Functioning, RE = 
Role Emotional, MH = Mental HealthBMC Public Health 2007, 7:186 http://www.biomedcentral.com/1471-2458/7/186
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results in tables 3 and 4, is the domain best predicted by
this set of variables (R2 = 0.42). Because of the relation-
ships observed in this study, as well as in others, it is rea-
sonable to conclude that any efforts to avoid or postpone
obesity, development of complications, hypertension,
hyperlipidaemia and other non-diabetic comorbid condi-
tions will enhance HRQOL and thereby improve healthy
life expectancy. However, efforts to prevent complications
of diabetes often overlook the impact of the condition
and its treatment on current quality of life HRQOL,
implying potential space for concurrently measuring
treatment satisfaction [43].
It is generally accepted that the prevalence of diabetes var-
ies among populations as a result of different environ-
mental influences and genetic susceptibility [44].
Furthermore, it has been clearly shown that urbanization
affects prevalence, with higher rates in urban areas than in
rural communities [45]. A recent Greek study involving
subjects in both urban and rural areas reported an age-
and sex-adjusted prevalence of DM of 10.6%, while undi-
agnosed diabetes was detected in 34% of the cases [46]. In
another study involving a municipality of rural Crete, a
relatively high age-standardized prevalence of DM of
5.2% was found [25].
In the present study, despite the inability to standardize
due to the lack of age and gender information of the entire
service population, the prevalence of type II DM in this
rural community appears to be relatively high (7.8%).
This implies that the findings from this study could have
important implications for health promotion in rural
medical practice in Greece. In terms of primary care for
example, modification of diabetes screening methods or
screening for diabetes patients at high risk for other dis-
eases could be steps in the direction of improving
HRQOL. Moreover, rural health policy should aim
towards new medical interventions and formulating dia-
betes educational programs for the local population,
addressing issues such as obesity, exercise and healthy
dieting as preventive measures against the disease.
The SF-36, commonly used in health services research,
was chosen as the measuring instrument because it is
fairly simple and comprehensible, not time-consuming to
answer, and has been previously validated with a repre-
sentative sample of the Greek population [29]. Further-
more, it is the typical choice when the primary research
aim is to measure HRQOL in a specified group rather than
to assess the effect of an intervention, in which case a dis-
ease-specific instrument should be used as well. A brief
comment on the psychometric properties of the instru-
ment in this particular study is that Cronbach's alpha
clearly exceeded the recommended 0.7 minimum in all
subscales, providing evidence of internal consistency and
that each subscale is measuring a distinct concept. Con-
struct validity is supported by the fact that older age, sex
(female), diabetic complications, non-diabetic comorbid-
ity and longer duration of diagnosed diabetes all gener-
ated impaired SF-36 scores, as was initially expected, and
these particular hypotheses have been previously used as
validity criteria of the instrument [18].
Our results generally correspond well to findings from
previous studies. For example, duration of diabetes was
identified as a significant HRQOL predictor in agreement
with other studies [6,47], although it has also been shown
that the two are insignificantly related [7,19]. The gender
effect is quite pronounced in the present study with a
worse impact on HRQOL in women. This is consistent
with reported gender differences in HRQOL in the general
population [29,30], and in studies involving people with
diabetes [6,48]. A noteworthy deviation from previous
findings is the marked effect of microvascular complica-
tions, in contrast to findings in most other studies, where
the macrovascular complications and the non-vascular
comorbidity show the greatest impact on HRQOL [42].
Although significant diabetes predictors have been identi-
fied in this and other studies, the associations do not
reveal the underlying mechanism, implying significant
space for future research.
This last point highlights a potential limitation to this
study. Specifically, concomitant chronic diseases and dia-
betic complications were self-reported, making it unfeasi-
ble to rank these data according to severity, and this could
have affected the results in the analyses, since light and
severe conditions were grouped together, hence diminish-
ing discriminative ability [42]. This is most likely the case
with comorbidity from which 95% of the sample suffers.
Furthermore, as studies are comparing diabetes samples
with samples from the general population [49,50], it
would be interesting to compare HRQOL in this patient
group, with an age- and gender-matched group from the
Greek rural population, in order to assess the specific
impact of the disease. A large-scale population study was
recently conducted in Greece, in which HRQOL and other
health-related variables were recorded and could be used
for forming well-matched general population and disease
subgroups for future comparisons.
Finally, one conceptualisation of HRQOL particular to
this category of diabetes is disease burden, including
patient distress due to diabetes symptoms, complications,
or treatment [51]. The use of diabetes-specific HRQOL
scales to assess troublesome symptoms and experiences
has been recommended for better sensitivity to burden
than the SF-36. Advancing age and other health problems
may influence health perceptions more than diabetes andBMC Public Health 2007, 7:186 http://www.biomedcentral.com/1471-2458/7/186
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undermine reductions in diabetes treatment burden, dia-
betes related symptoms or disease consequences.
Conclusion
To conclude, this study has shown Type II DM negatively
affects HRQOL in this Greek rural population, particularly
in relation to their physical functioning, and that com-
mon sociodemographic and clinical indicators such as
diabetic complications and non-diabetic comorbidity are
important in targeting those at high risk of developing the
disease. However, comparison to a control group is
required to assess the magnitude of this effect. As the prev-
alence of DM increases, the disease places more demands
on medical care and expenditure. Programs addressing
the physical and mental needs of the population are
required, especially older people with chronic diseases.
The prevention of diabetes, or at least delaying its compli-
cations, should become a health priority addressed
through education programs delivered to urban and rural
citizens.
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